Artificial pancreas developer Bigfoot Biomedical said today that it acquired Patients Pending and its connected insulin pen technology for an undisclosed amount.
With this acquisition, Bigfoot said it is the 1st company to simultaneously pursue both insulin infusion and injection delivery solutions.
Get the full story at our sister site, Drug Delivery Business News.
The post Bigfoot buys connected insulin pen tech appeared first on MassDevice.